Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
During the past 12 months, Hisamitsu Pharmaceutical Co's average EBITDA Per Share Growth Rate was -9.50% per year.
During the past 3 years, the average EBITDA Per Share Growth Rate was 17.50% per year.
During the past 5 years, the average EBITDA Per Share Growth Rate was 20.20% per year.
During the past 10 years, the average EBITDA Per Share Growth Rate was -1.50% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
During the past 13 years, the highest 3-Year average EBITDA Per Share Growth Rate of Hisamitsu Pharmaceutical Co was 30.80% per year. The lowest was -20.90% per year. And the median was -1.30% per year.
Hisamitsu Pharmaceutical Co (FSE:4530) 5-Year EBITDA Growth Rate Explanation
EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.
Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.
5-Year EBITDA Growth Rate gives an overview of the company's growth in operating profitability and is an important factor used in calculating Peter Lynch Fair Value.
Hisamitsu Pharmaceutical Co 5-Year EBITDA Growth Rate Related Terms
FSE:4530 vs AMPH, ESPR, NIKA: 5-Year EBITDA Growth Rate Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Hisamitsu Pharmaceutical Co's 5-Year EBITDA Growth Rate, along with its competitors' market caps and 5-Year EBITDA Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Hisamitsu Pharmaceutical Co 5-Year EBITDA Growth Rate vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Hisamitsu Pharmaceutical Co's 5-Year EBITDA Growth Rate distribution charts can be found below:
* The bar in red indicates where Hisamitsu Pharmaceutical Co's 5-Year EBITDA Growth Rate falls into.
Hisamitsu Pharmaceutical Co 5-Year EBITDA Growth Rate Calculation
This is the 5-year average growth rate of EBITDA per Share. The growth rate is calculated with least square regression.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
What does a 5-Year EBITDA Growth Rate of 20.20% mean?
Hisamitsu Pharmaceutical Co (FSE:4530) has a 5-Year EBITDA Growth Rate of 20.20% as of Nov. 2025. 5-Year EBITDA Growth Rate is the 5-year average growth rate of EBITDA per share. View historical data for Hisamitsu Pharmaceutical Co and its competitors.
Is Hisamitsu Pharmaceutical Co's 5-Year EBITDA Growth Rate too high?
Hisamitsu Pharmaceutical Co's current 5-Year EBITDA Growth Rate is 20.20%. Overall, Hisamitsu Pharmaceutical Co has a GF Score™ of 89/100, reflecting its overall financial health beyond just this single metric.
How does Hisamitsu Pharmaceutical Co's 5-Year EBITDA Growth Rate compare to AMPH and ESPR?
Hisamitsu Pharmaceutical Co's 5-Year EBITDA Growth Rate of 20.20% can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 5-Year EBITDA Growth Rate for a Drug Manufacturers company?
A good 5-Year EBITDA Growth Rate depends on the Drug Manufacturers industry context. However, 5-Year EBITDA Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 5-Year EBITDA Growth Rate mean?
A high 5-Year EBITDA Growth Rate can signal that a stock is expensive relative to its fundamentals. 5-Year EBITDA Growth Rate is the 5-year average growth rate of EBITDA per share. View historical data for Hisamitsu Pharmaceutical Co and its competitors. Hisamitsu Pharmaceutical Co's current 5-Year EBITDA Growth Rate is 20.20%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Hisamitsu Pharmaceutical Co stock overvalued right now?
Hisamitsu Pharmaceutical Co (FSE:4530) has a current 5-Year EBITDA Growth Rate of 20.20%. The stock's GF Value™ is 円3,237.07, compared to a current price of 円3,975.00 — trading 22.8% above its estimated fair value. The current 5-Year EBITDA Growth Rate is 20.20%. Hisamitsu Pharmaceutical Co's overall GF Score™ is 89/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 5-Year EBITDA Growth Rate calculated?
5-Year EBITDA Growth Rate is calculated from a company's financial statements. For Hisamitsu Pharmaceutical Co (FSE:4530), the current 5-Year EBITDA Growth Rate is 20.20% as of Nov. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Hisamitsu Pharmaceutical Co (FSE:4530) Overvalued in 2026?
Based on GuruFocus' analysis, Hisamitsu Pharmaceutical Co stock appears to be overvalued.
The current stock price of 円3,975.00 is trading 22.8% above its estimated GF Value™ of 円3,237.07.
Key valuation signals for FSE:4530:
5-Year EBITDA Growth Rate: 20.20%
GF Value™: 円3,237.07 vs. price of 円3,975.00 (22.8% above fair value)
No single metric tells the full story. See the FSE:4530 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Hisamitsu Pharmaceutical Co Inc is engaged in the research, development, manufacturing, procurement, and sale of pharmaceutical products. The company operates a single business segment, focusing on medical and general pharmaceuticals both in Japan and overseas. It markets drugs under the Salonpas, Nobinobi / Salonsip, Butenalock, and Mohrus brands, which mainly serve topical medication needs with pain relief creams, gels, sprays, lotions, and ointments.
89GF Score
Get the complete analysis for FSE:4530
5-Year EBITDA Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FSE:4530 has been successfully added to your 
